S 898 United States Senate · 117th Congress

Fair Accountability and Innovative Research Drug Pricing Act of 2021

Summary
Fair Accountability and Innovative Research Drug Pricing Act of 20 21 This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
Bill status in committee 1 of 4 stages cleared
Introduction
Mar 2021
Committee Review
Floor Vote
President
Introduced Mar 23, 2021 Last action Mar 23, 2021
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
Mar 23, 2021
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
upper
Mar 23, 2021
Introduced
Introduced in Senate
upper
1 primary · 5 co-sponsors

Sponsors